Galectin Therapeutics Inc... (GALT)
NASDAQ: GALT
· Real-Time Price · USD
3.57
-0.19 (-5.05%)
At close: Aug 15, 2025, 3:59 PM
3.55
-0.56%
After-hours: Aug 15, 2025, 06:50 PM EDT
Galectin Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -9.63M | -11.97M | -11.22M | -12.37M | -11.49M | -10M | -10.43M | -9.11M | -11.53M | -10.63M | -8.6M | -9.61M | -9.93M | -7.22M | -8.52M | -8.45M | -6.34M |
Depreciation & Amortization | 10K | 10K | 9K | 9K | 9K | 9K | 8K | -16K | 32K | 8K | 7K | 7K | 10K | 11K | 10K | 10K | 10K |
Stock-Based Compensation | 468K | 590K | 515K | 738K | 604K | 497K | 586K | 516K | 662K | 681K | 681K | 647K | 858K | 654K | 587K | 581K | 254K |
Other Working Capital | n/a | 847K | -672K | 1.24M | 988K | -143K | 894K | 757K | 499K | -496K | 468K | 445K | 307K | -860K | 396K | 298K | 289K |
Other Non-Cash Items | n/a | -1.75M | 3M | 141K | 1.08M | -145K | 682K | 169K | 913K | -143K | 342K | -197K | -149K | -204K | 12K | 257K | 22K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -490K | n/a | n/a | n/a | n/a | n/a | n/a | 166K | n/a | n/a |
Change in Working Capital | n/a | 326K | -845K | 3.15M | -2.31M | 4.93M | 1.51M | -898K | -873K | 2.85M | -780K | 1.73M | 1.17M | -191K | 2.75M | 1.62M | -330K |
Operating Cash Flow | -7.69M | -12.79M | -8.54M | -8.33M | -12.11M | -4.7M | -7.64M | -9.83M | -10.79M | -7.24M | -8.35M | -7.43M | -8.04M | -6.95M | -5M | -5.98M | -6.38M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | 10M | 10M | 10M | n/a | 10M | 10M | 10M | n/a | n/a | n/a | 10M | 10M | n/a | n/a |
Common Stock Repurchased | n/a | n/a | 568K | n/a | 277K | 374K | n/a | n/a | n/a | 899K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | -62K | n/a | -18K | n/a | n/a | n/a | n/a | n/a | n/a | -48K | n/a | n/a | -49K | n/a | n/a | n/a | -67K |
Other Financial Acitivies | n/a | 851K | 10.02M | 376K | n/a | n/a | 10.03M | n/a | n/a | 48K | n/a | n/a | n/a | n/a | n/a | 10M | 67K |
Financial Cash Flow | n/a | 851K | 10M | 10.38M | 10M | 10M | 10.03M | 10M | 10M | 10M | n/a | n/a | n/a | 10M | 10M | 16.82M | n/a |
Net Cash Flow | -7.69M | -11.94M | 1.46M | 2.04M | -2.1M | 5.3M | 2.4M | -33K | -593K | 2.76M | -8.35M | -7.43M | -8.04M | 3.05M | 5M | 10.84M | -6.38M |
Free Cash Flow | -7.69M | -12.79M | -8.54M | -8.33M | -12.11M | -4.7M | -7.64M | -9.83M | -10.79M | -7.24M | -8.35M | -7.43M | -8.04M | -6.95M | -5M | -5.98M | -6.38M |